SCHEMBL7033102

SCHEMBL7033102

COC(=O)NC(C)C(=O)O.c1cc2cc(c1)S2

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.38
TYR P14679 1/20 0.37
LTA4H P09960 1/20 0.36
MME P08473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444915 0.78 MME (0.41) SMN1; SMN2KDM4EALDH1A1MEN1TSHR
SCHEMBL194101 0.78 MME (0.41) SMN1; SMN2KDM4EALDH1A1MEN1TSHR
SCHEMBL194100 0.78 MME (0.41) SMN1; SMN2KDM4EALDH1A1MEN1TSHR
SCHEMBL10578705 0.77 PTGS2 (0.39) HSD17B10SMN1; SMN2KDM4EALDH1A1MEN1
Alanine SCHEMBL2176579 0.71 MME (0.36) SMN1; SMN2KDM4EALDH1A1TSHRTYR
SCHEMBL7324309 0.71 MME (0.44) SMN1; SMN2LMNATYRLTA4HMME
SCHEMBL7324302 0.71 MME (0.44) SMN1; SMN2LMNATYRLTA4HMME
SCHEMBL7033296 0.71 SHMT1 (0.37) SMN1; SMN2KDM4E
SCHEMBL18794691 0.70 KMT2A (0.45) SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL10949351 0.69 TSHR (0.48) KDM4EALDH1A1TSHRKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975601-B1 PROCESS FOR MAKING A BUTYLTHIO-ISOQUINOLINE AND INTERMEDIATES THEREFOR HOFFMANN LA ROCHE (CH) 2003-03-12 EP claimed
US-20010018538-A1 New process for a phenylthiobutyl-isoquinoline and intermediates therefor HILPERT HANS (CH) 2001-08-30 US claimed
US-6239296-B1 Process for a phenylthiobutyl-isoquinoline and intermediates therefor HOFFMANN-LA ROCHE INC. 2001-05-29 US claimed
EP-0975601-A1 PROCESS FOR MAKING A BUTYLTHIO-ISOQUINOLINE AND INTERMEDIATES THEREFOR F. HOFFMANN-LA ROCHE AG (CH) 2000-02-02 EP claimed
WO-1998045271-A1 PROCESS FOR MAKING A BUTYLTHIO-ISOQUINOLINE AND INTERMEDIATES THEREFOR F. HOFFMAN-LA ROCHE AG (CH) 1998-10-15 WO claimed
EP-0975601-B1 PROCESS FOR MAKING A BUTYLTHIO-ISOQUINOLINE AND INTERMEDIATES THEREFOR HOFFMANN LA ROCHE (CH) 2003-03-12 EP disclosed
US-6437134-B2 SILYLATING THE CORRESPONDING CARBAMATE COMPOUND; ALKYLATION HOFFMANN-LA ROCHE INC. 2002-08-20 US disclosed
US-20010018538-A1 New process for a phenylthiobutyl-isoquinoline and intermediates therefor HILPERT HANS (CH) 2001-08-30 US disclosed
US-6239296-B1 Process for a phenylthiobutyl-isoquinoline and intermediates therefor HOFFMANN-LA ROCHE INC. 2001-05-29 US disclosed
US-6130348-A Process for a phenylthiobutyl-isoquinoline and intermediates therefor HOFFMANN-LA ROCHE INC. (US) 2000-10-10 US disclosed
EP-0975601-A1 PROCESS FOR MAKING A BUTYLTHIO-ISOQUINOLINE AND INTERMEDIATES THEREFOR F. HOFFMANN-LA ROCHE AG (CH) 2000-02-02 EP disclosed
WO-1998045271-A1 PROCESS FOR MAKING A BUTYLTHIO-ISOQUINOLINE AND INTERMEDIATES THEREFOR F. HOFFMAN-LA ROCHE AG (CH) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018538-A1 New process for a phenylthiobutyl-isoquinoline and intermediates therefor WEE1, WEE2, CYP4F11 HSD17B10 972/4885SMN1; SMN2 4233/4885KDM4E 3526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.